| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Pedro Weslley Rosario, Maria Regina Calsolar. Safety and specificity of the growth hormone suppression test in patients with diabetes. Endocrine. vol 48. issue 1. 2015-11-10. PMID:24833548. |
among the 130 diabetic patients without known pituitary disease or a clinical suspicion of acromegaly, 95.5% of men, 94% of premenopausal women, and 96.6% of postmenopausal women presented adequate gh suppression (vs 97.5% of normoglycemic controls). |
2015-11-10 |
2023-08-13 |
human |
| Pedro Weslley Rosario, Maria Regina Calsolar. Safety and specificity of the growth hormone suppression test in patients with diabetes. Endocrine. vol 48. issue 1. 2015-11-10. PMID:24833548. |
in all patients without acromegaly, the lowest gh levels (nadir) were achieved after the administration of glucose and not during baseline measurement. |
2015-11-10 |
2023-08-13 |
human |
| Pedro Weslley Rosario, Maria Regina Calsolar. Safety and specificity of the growth hormone suppression test in patients with diabetes. Endocrine. vol 48. issue 1. 2015-11-10. PMID:24833548. |
we demonstrated the safety of the ogtt and its capacity to suppress gh in diabetic patients without acromegaly. |
2015-11-10 |
2023-08-13 |
human |
| Pedro Weslley Rosario, Maria Regina Calsolar. Laboratory investigation of acromegaly: is basal or random GH > 0.4 µg/L in the presence of normal serum IGF-1 an important result? Archives of endocrinology and metabolism. vol 59. issue 1. 2015-10-29. PMID:25926115. |
laboratory investigation of acromegaly: is basal or random gh > 0.4 µg/l in the presence of normal serum igf-1 an important result? |
2015-10-29 |
2023-08-13 |
Not clear |
| Pedro Weslley Rosario, Maria Regina Calsolar. Laboratory investigation of acromegaly: is basal or random GH > 0.4 µg/L in the presence of normal serum IGF-1 an important result? Archives of endocrinology and metabolism. vol 59. issue 1. 2015-10-29. PMID:25926115. |
to determine the frequency of indication of the gh suppression test and pituitary magnetic resonance imaging (mri) in patients with clinical suspicion of acromegaly with gh concentrations > 0.4 µg/l despite normal serum igf-1. |
2015-10-29 |
2023-08-13 |
Not clear |
| Julie M Silverstei. Need for improved monitoring in patients with acromegaly. Endocrine connections. vol 4. issue 4. 2015-10-16. PMID:26381160. |
acromegaly is a rare and insidious disease characterized by the overproduction of growth hormone (gh) and insulin-like growth factor 1 (igf1) and is most commonly due to a pituitary adenoma. |
2015-10-16 |
2023-08-13 |
Not clear |
| Julie M Silverstei. Need for improved monitoring in patients with acromegaly. Endocrine connections. vol 4. issue 4. 2015-10-16. PMID:26381160. |
patients with acromegaly who experience prolonged exposure to elevated levels of gh and igf1 have an increased mortality risk and progressive worsening of disease-related comorbidities. |
2015-10-16 |
2023-08-13 |
Not clear |
| Julie M Silverstei. Need for improved monitoring in patients with acromegaly. Endocrine connections. vol 4. issue 4. 2015-10-16. PMID:26381160. |
multimodal treatment with surgery, medical therapy, and radiotherapy provides biochemical control, defined by recent acromegaly clinical guidelines from the endocrine society as a reduction of gh levels to <1.0 ng/ml and normalization of igf1 levels, to a substantial proportion of patients and is associated with improved clinical outcomes. |
2015-10-16 |
2023-08-13 |
Not clear |
| Julie M Silverstei. Need for improved monitoring in patients with acromegaly. Endocrine connections. vol 4. issue 4. 2015-10-16. PMID:26381160. |
patients with acromegaly, even those without clinical symptoms of disease, require long-term monitoring of gh and igf1 levels if the benefits associated with biochemical control are to be maintained and the risk of developing recurrent disease is to be abated. |
2015-10-16 |
2023-08-13 |
Not clear |
| Julie M Silverstei. Need for improved monitoring in patients with acromegaly. Endocrine connections. vol 4. issue 4. 2015-10-16. PMID:26381160. |
because of the significant health consequences associated with prolonged exposure to elevated levels of gh and igf1, optimal monitoring in patients with acromegaly is needed. |
2015-10-16 |
2023-08-13 |
Not clear |
| Stephan Petersenn, Jens Bollerslev, Ayman M Arafat, Jochen Schopohl, Omar Serri, Laurence Katznelson, Janet Lasher, Gareth Hughes, Ke Hu, George Shen, Karina Hermosillo Reséndiz, Vanessa Giannone, Albert Becker. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. Journal of clinical pharmacology. vol 54. issue 11. 2015-10-13. PMID:24800725. |
control of gh, igf-1, and symptoms improved, suggesting that pasireotide lar may be an effective treatment for acromegaly. |
2015-10-13 |
2023-08-13 |
Not clear |
| Moises Mercado, Baldomero Gonzalez, Guadalupe Vargas, Claudia Ramirez, Ana Laura Espinosa de los Monteros, Ernesto Sosa, Paola Jervis, Paola Roldan, Victoria Mendoza, Blas López-Félix, Gerardo Guint. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. The Journal of clinical endocrinology and metabolism. vol 99. issue 12. 2015-10-07. PMID:25210882. |
acromegaly is usually due to the excessive secretion of gh by a pituitary adenoma. |
2015-10-07 |
2023-08-13 |
Not clear |
| Mehdi Zeinalizadeh, Zohreh Habibi, Juan C Fernandez-Miranda, Paul A Gardner, Steven P Hodak, Sue M Challino. Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management. Pituitary. vol 18. issue 1. 2015-10-05. PMID:24496953. |
follow-up management of patients with acromegaly after pituitary surgery is performed by conducting biochemical assays of growth hormone (gh) and insulin-like growth factor-1 (igf1). |
2015-10-05 |
2023-08-12 |
Not clear |
| Michael Sheppard, Marcello D Bronstein, Pamela Freda, Omar Serri, Laura De Marinis, Luciana Naves, Liudmila Rozhinskaya, Karina Hermosillo Reséndiz, Matthieu Ruffin, YinMiao Chen, Annamaria Cola. Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary. vol 18. issue 3. 2015-09-11. PMID:25566750. |
erratum to: pasireotide lar maintains inhibition of gh and igf-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase iii study. |
2015-09-11 |
2023-08-13 |
Not clear |
| Tove Lekva, Jens Petter Berg, Robert Lyle, Ansgar Heck, Jens Bollerslev, Thor Uelan. Alternative splicing of placental lactogen (CSH2) in somatotroph pituitary adenomas. Neuro endocrinology letters. vol 36. issue 2. 2015-09-08. PMID:26071582. |
somatotroph adenomas secrete supraphysiological amounts of gh, causing acromegaly. |
2015-09-08 |
2023-08-13 |
Not clear |
| Christa C van Bunderen, Nadège C van Varsseveld, Martijn W Heymans, Anton A M Franken, Hans P F Koppeschaar, Aart J van der Lely, Madeleine L Dren. Effect of long-term GH replacement therapy on cardiovascular outcomes in GH-deficient patients previously treated for acromegaly: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults. European journal of endocrinology. vol 171. issue 6. 2015-07-08. PMID:25227133. |
effect of long-term gh replacement therapy on cardiovascular outcomes in gh-deficient patients previously treated for acromegaly: a sub-analysis from the dutch national registry of growth hormone treatment in adults. |
2015-07-08 |
2023-08-13 |
Not clear |
| Christa C van Bunderen, Nadège C van Varsseveld, Martijn W Heymans, Anton A M Franken, Hans P F Koppeschaar, Aart J van der Lely, Madeleine L Dren. Effect of long-term GH replacement therapy on cardiovascular outcomes in GH-deficient patients previously treated for acromegaly: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults. European journal of endocrinology. vol 171. issue 6. 2015-07-08. PMID:25227133. |
the effect of gh deficiency (ghd) on the metabolic profile of acromegaly patients is unclear in patients previously treated for acromegaly, as are the efficacy and safety of gh treatment in this particular group. |
2015-07-08 |
2023-08-13 |
Not clear |
| Christa C van Bunderen, Nadège C van Varsseveld, Martijn W Heymans, Anton A M Franken, Hans P F Koppeschaar, Aart J van der Lely, Madeleine L Dren. Effect of long-term GH replacement therapy on cardiovascular outcomes in GH-deficient patients previously treated for acromegaly: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults. European journal of endocrinology. vol 171. issue 6. 2015-07-08. PMID:25227133. |
the aim of the study is to describe the characteristics of patients with severe ghd who were previously treated for acromegaly, and to investigate the effects of long-term gh treatment on cardiovascular risk factors and morbidity, compared with patients who were treated for a nonfunctioning pituitary adenoma (nfpa). |
2015-07-08 |
2023-08-13 |
Not clear |
| A J Varewijck, S W J Lamberts, A J van der Lely, S J C M M Neggers, L J Hofland, J A M J L Jansse. The introduction of the IDS-iSYS total IGF-1 assay may have far-reaching consequences for diagnosis and treatment of GH deficiency. The Journal of clinical endocrinology and metabolism. vol 100. issue 1. 2015-07-08. PMID:25337924. |
igf-1 measurements are used for screening and monitoring gh deficiency (ghd) and acromegaly. |
2015-07-08 |
2023-08-13 |
Not clear |
| Sauradeep Sarkar, Ari George Chacko, Geeta Chack. An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly. Acta neurochirurgica. vol 156. issue 12. 2015-07-07. PMID:25238988. |
the authors sought to comprehensively examine clinical and radiological correlates of growth hormone (gh)-secreting pituitary adenomas with regard to several commonly used immunocytochemical techniques in patients undergoing transsphenoidal surgery for acromegaly. |
2015-07-07 |
2023-08-13 |
Not clear |